Business
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs
BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month
About this update from Bridgebio Oncology Therapeutics, Inc.
[{"type":"text","content":"BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients eligible for 6-month follow-up remaining on treatment for ≥6 months, alongside a potentially differentiated safety profile. Encouraging early efficacy signals were seen in patients with KRASG12C and STK11 and/or KEAP1 co-mutants, where all five initial patients achieved partial response.BBO-8520 in combination with pembrolizumab, at active dose levels, demonstrated promising efficacy data and a distinct, differentiated safety profile. A favorable liver safety profile was observed compared with pembrolizumab monotherapy.BBO-11818 monotherapy demonstrated a confirmed partial response (PR) in pancreatic cancer and anti-tumor activity was observed across dose levels and tumor types with tumor reductions at higher dose levels with a generally favorable, differentiated safety profile in dose escalation.BBO-10203 demonstrated a potentially differentiated safety profile without any observed events of hyperglycemia and without any enrollment restrictions on baseline HbA1c and glucose levels; combination studies with standard-of-care (SOC) treatments in colorectal cancer (CRC) and breast cancer (BC) have been initiated; internal combination studies with BBO-8520 and BBO-11818 are anticipated to open this year.Company webcast to be held today at 8:30 a.m. Eastern Time (ET). SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced positive preliminary safety and antitumor data across its three orally bioavailable, differentiated small molecule RAS and PI3Kα programs. The data updates include BBO-8520, a direct inhibitor targeting both the ON and OFF states of KRASG12C; BBO-11818, a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states, and BBO-10203, a RAS-PI3Ka breaker with a novel mechanism of action designed to inhibit the physical interaction between RAS and PI3Kα. “Today’s data underscore the strength of our differentiated precision oncology portfolio targeting RAS and PI3Kα,” said Eli Wallace, PhD, Chief Executive Officer of BBOT. “By focusing on ON biology and le...